Breast Cancer PSMA PET
Recruiting · NCT06586047 · Interventional (participants receive a specific treatment) · Lead sponsor: Ahmad Shariftabrizi
View the official record on ClinicalTrials.gov →Interventions studied
PET imaging
What this trial is about
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Who can take part
Age range
18 Years to 90 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Female \>= 18 years of age
- Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
- Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
Exclusion criteria
- Patients with known active other malignancy.
- Unable to tolerate PET/CT procedure.
- Pregnant or breastfeeding.
- Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Where it is running
1 location listed across 1 US state.
- University of Iowa Healthcare - Iowa City, Iowa, United States